A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Local Institution - 401, Zurich

Local Institution - 175, Melbourne

Local Institution - 403, Basel

Local Institution - UNK-121, Yvoir

Local Institution - 177, Perth

Local Institution - 376, Cáceres

Local Institution - 251, Orbassano

Local Institution - 106, New York

Local Institution - 227, Berlin

Local Institution - 206, Marseille

Local Institution - 256, Genova

Local Institution - 378, Madrid

Local Institution - 381, Madrid

Local Institution - 380, Málaga

Local Institution - 203, Toulouse

Local Institution - 250, Pesaro

Local Institution - 204, Pessac

Local Institution - 254, Padua

Local Institution - 253, Bologna, Emilia-Romagna

Local Institution - 377, Valencia

Local Institution - 252, Florence

Local Institution - 205, Lille

Local Institution - 108, Chicago

Local Institution - 103, Chicago

Local Institution - 202, Pierre-Bénite

Local Institution - 200, Paris

Local Institution - 225, Ulm

Local Institution - 201, Villejuif

Local Institution - 105, Duarte

Local Institution - 107, New Haven

Local Institution - 102, Boston

Beth Israel Deaconess Medical Center, Boston

Local Institution - 902, Boston

Local Institution - 110, Dallas

Local Institution - 178, Adelaide

Local Institution - 125, Toronto

Local Institution - 230, Dresden

Local Institution - 255, Roma

Local Institution - 277, Utrecht

Local Institution - 327, Lisbon

Local Institution - 351, Seoul

Local Institution - 350, Seoul

Local Institution - 379, Barcelona

Local Institution - 375, Barcelona

Local Institution - UNK-52, Gothenburg

Local Institution - 429, Birmingham

Local Institution - 427, Headington

Local Institution - 428, London

Local Institution - 430, Sutton (Surrey)